Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sutent · 1 trial · 1 indication
Disease control rate = CR + PR + SD\>=6-weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. Stable Disease (SD) is defined as persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.
| Arm | Type | Description |
|---|---|---|
| Sunitinib Malate | EXPERIMENTAL | Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle. |
| Name | Type | Description |
|---|---|---|
| Sutent | DRUG | Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle. |
Inclusion Criteria: * Has measurable, metastatic NSCLC, other elderly NSCLC patients over 70 years of age who are not felt to be candidates for standard chemotherapy at the discretion of the treating physician may also be enrolled as long as they meet the criteria; these "special consideration" pat...
Top 20 of 84 competitors
Sutent is being studied for use in Non Small Cell Lung Cancer, specifically in patients over 70 years old. It is an investigational small molecule oncology drug currently in Phase 2 clinical development. The completed clinical trial enrolled 63 participants in the United States.
Sutent is developed by McKesson Corporation, which trades under the ticker symbol MCK. The company is conducting clinical research on this small molecule for the treatment of Non Small Cell Lung Cancer.
Sutent is in Phase 2 clinical development for Non Small Cell Lung Cancer. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, with no active trials currently ongoing.
Sutent has one completed clinical trial registered as NCT00864721, titled 'Sunitinib Non Small Cell Lung Cancer Patients Over 70'. This Phase 2 study enrolled 63 patients with Non Small Cell Lung Cancer in the United States, with a minimum age of 70 years.
Sutent is not FDA approved for Non Small Cell Lung Cancer. It is an investigational drug currently in Phase 2 clinical development. The completed trial NCT00864721 was uncontrolled and not randomized or double-blinded, indicating early-stage research.
Sutent is a small molecule drug being studied for Non Small Cell Lung Cancer. The specific molecular target has not been disclosed in the available clinical trial information. It is being evaluated in a biomarker-selected patient population.